Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | F12 | P00748 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | C5AR1 | P21730 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.39 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.38 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16217171 | 0.85 | MAPT (0.43) | ADORA1NR1H2F12MAPTESR2 | |
| SCHEMBL16220618 | 0.85 | MAPT (0.43) | ADORA1NR1H2F12MAPTESR2 | |
| SCHEMBL16579807 | 0.84 | MAPT (0.42) | ADORA1NR1H2F12MAPTESR2 | |
| SCHEMBL20424298 | 0.82 | DPP4 (0.46) | ADORA1NR1H2F12MAPTESR2 | |
| SCHEMBL22438669 | 0.81 | MAPT (0.43) | ADORA1NR1H2F12MAPTESR2 | |
| SCHEMBL16210205 | 0.81 | MAPT (0.40) | ADORA1NR1H2F12MAPTESR2 | |
| SCHEMBL22438969 | 0.80 | ESR2 (0.42) | ADORA1NR1H2F12MAPTESR2 | |
| SCHEMBL22438692 | 0.79 | NR1H2 (0.41) | ADORA1NR1H2F12MAPTESR2 | |
| SCHEMBL22831727 | 0.79 | ESR2 (0.41) | ADORA1NR1H2F12MAPTESR2 | |
| SCHEMBL22615303 | 0.78 | ADORA1 (0.51) | ADORA1NR1H2F12MAPTESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210079015-A1 | NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | disclosed |
| US-20210079015-A1 | NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | NOVARTIS AG (CH) | 2021-03-18 | — | — | US | disclosed |
| EP-3759110-A1 | INDOLE-2-CARBONYL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | Novartis AG (CH) | 2021-01-06 | — | — | EP | disclosed |
| US-20200407365-A1 | INDOLE-2-CARBONYL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2020-12-31 | — | — | US | disclosed |
| US-20200407365-A1 | INDOLE-2-CARBONYL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. | 2020-12-31 | — | — | US | disclosed |
| EP-3710455-A1 | NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | Novartis AG (CH) | 2020-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210079015-A1 | NOVEL DIHYDROISOXAZOLE COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | XDH, SLC10A1, RORB | ADORA1 850/4885NR1H2 25/4885F12 9/4885 |
| US-20200407365-A1 | INDOLE-2-CARBONYL COMPOUNDS AND THEIR USE FOR THE TREATMENT OF HEPATITIS B | IDO2, IDO1, SLC10A1 | ADORA1 1150/4885NR1H2 82/4885F12 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.